Latest news with #MyelodysplasticSyndrome
Yahoo
a day ago
- Business
- Yahoo
Myelodysplastic Syndrome Competitive Landscape 2025: 262 Molecules in MDS Pipeline - A Peek into Future Therapeutics
Discover the competitive landscape of Myelodysplastic Syndrome (MDS) therapeutics. With 498,757 cases in 2024 and a slight increase by 2029, the report reveals a robust pipeline of 262 molecules and over 1,200 clinical trials. Uncover key market players, future catalysts, and strategic insights for effective market positioning. Dublin, June 05, 2025 (GLOBE NEWSWIRE) -- The "Myelodysplastic Syndrome: Competitive Landscape" report has been added to reports provides a data-driven overview of the current and future competitive landscape in Myelodysplastic Syndrome Therapeutics. The analyst epidemiologists estimate that there were 498,757 diagnosed prevalent cases of Myelodysplastic Syndrome (MDS) infection in 2024, which is expected to increase slightly to 557,730 diagnosed prevalent cases by 2029. MDS is managed through a combination of supportive care, chemotherapy, and targeted therapies. The MDS pipeline holds 262 molecules, with two assets in the pre-registration stage, 16 assets in Phase III development, and 87 assets in Phase II. Over the past decade, 1,229 clinical trials have been conducted in MDS. During the past decade, partnerships were most prevalent in North America and Europe. Report ScopeThe Myelodysplastic Syndrome Therapeutics: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease of the report include: Disease Landscape Disease Overview Epidemiology Overview Treatment Overview Marketed Products Assessment Breakdown by Mechanism of Action, Route of Administration Product Profiles with Sales Forecast Pricing and Reimbursement Assessment Annual Therapy Cost Time to Pricing and Time to Reimbursement Pipeline Assessment Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration Product Profiles with Sales Forecast Late-to-mid-stage Pipeline Drugs Phase Transition Success Rate and Likelihood of Approval Clinical Trials Assessment Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status Enrolment Analytics, Site Analytics, Feasibility Analysis Deals Landscape Mergers, Acquisitions, and Strategic Alliances by Region Overview of Recent Deals Commercial Assessment Key Market Players Future Market Catalysts Reasons to Buy Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Develop business strategies by understanding the trends shaping and driving the Myelodysplastic Syndrome Therapeutics market. Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Myelodysplastic Syndrome Therapeutics market in the future. Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors. Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships. Key Topics Covered: 1 Preface2 Key Findings3 Disease Landscape3.1 Disease Overview3.2 Epidemiology Overview3.3 Treatment Overview4 Marketed Drugs Assessment4.1 Leading Marketed Drugs4.2 Overview by Mechanism of Action4.3 Overview by Molecule Type4.4 Product Profiles and Sales Forecast5 Pricing and Reimbursement Assessment5.1 Annual Cost of Therapy5.2 Time to Pricing and Reimbursement6 Pipeline Drugs Assessment6.1 Mid-to-late-stage Pipeline Drugs6.2 Overview by Development Stage6.3 Overview by Mechanism of Action6.4 Overview by Molecule Type6.5 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)6.6 Therapy Area and Indication-specific PTSR and LoA7 Clinical Trials Assessment7.1 Historical Overview7.2 Overview by Phase7.3 Overview by Status7.4 Overview by Phase for Ongoing and Planned Trials7.5 Trials with Virtual Components7.6 Overview of Trials by Geography7.7 Single-Country and Multinational Trials by Region7.8 Top 20 Sponsors with Breakdown by Phase7.9 Top 20 Sponsors with Breakdown by Status7.10 Overview by Endpoint Status7.11 Overview by Race and Ethnicity7.12 Enrollment Data7.13 Top 20 countries for Trial Sites7.14 Top 20 Sites Globally7.15 Feasibility Analysis - Geographic Overview7.16 Feasibility Analysis - Benchmark Models8 Deals Landscape8.1 Mergers, Acquisitions, and Strategic Alliances by Region8.2 Recent Mergers, Acquisitions, and Strategic Alliances9 Commercial Assessment9.1 Key Market Players10 Future Market CatalystsFor more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Associated Press
2 days ago
- Business
- Associated Press
Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for Myelodysplastic Syndrome (MDS)
LEHI, Utah, June 4, 2025 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering therapies inspired by genetic resilience, today announced the completion of enrollment for its open-label Phase 2a clinical trial evaluating HT-6184 (Ofirnoflast) in patients with lower-risk Myelodysplastic Syndrome (MDS) who are refractory to, intolerant of, or ineligible for erythropoiesis-stimulating agents (ESA). The study ( CTRI/2023/11/059758 ) is designed to evaluate the efficacy, safety, and biomarker response of HT-6184, a novel allosteric modulator of NEK7 that disrupts NEK7–NLRP3 protein interaction, thereby preventing the formation of the NLRP3 inflammasome. This mechanism also promotes the disassembly of pre-formed NLRP3 inflammasomes, targeting a key inflammatory pathway implicated in bone marrow dysfunction in myelodysplastic syndromes (MDS). The two-stage study enrolled 18 evaluable patients in Stage 1 and has now completed enrollment of an additional 15 participants in Stage 2. 'Completing enrollment in our Phase 2a MDS study is a major milestone as we continue to validate our mechanism of action targeting innate immune dysregulation,' said Dr. David Bearss, CEO of Halia Therapeutics. 'This study provides important proof-of-concept data to support the therapeutic potential of HT-6184 in reducing clonal inflammation and improving hematologic outcomes for patients with symptomatic anemia.' The trial consists of a 16-week treatment period, followed by a response-based continuation phase. Responders may continue on therapy, while non-responders showing a greater than 30% reduction in variant allele frequency (VAF) clone size may receive up to 16 additional weeks of treatment, either as monotherapy or in combination with prior ESA therapy. Key study objectives include evaluating efficacy through hematological improvement, clonal suppression, and VAF reduction, assessing safety and patient tolerance, monitoring changes in inflammasome-related biomarkers, and measuring quality of life using patient-reported outcome tools. An interim analysis was conducted following Stage 1, and topline results from the complete study are expected later this year. About Halia Therapeutics Halia Therapeutics is redefining treatment paradigms by targeting the innate immune system and harnessing genetic resilience. Founded on breakthrough research identifying protective mutations in individuals genetically predisposed to severe diseases, Halia's therapies aim to restore immune balance in inflammatory and neurodegenerative conditions. The company's pipeline includes: For more information about Ofirnoflast (HT-6184), HT-4253, or ongoing clinical trials, please visit Media Contact Taylor Avei Director of Business Development Halia Therapeutics [email protected] View original content to download multimedia: SOURCE Halia Therapeutics
Yahoo
07-05-2025
- Health
- Yahoo
Faith, family and friendship on display at Dowling Catholic as Foth family fights childhood cancer repercussions
DES MOINES, Iowa — Faith, family, and friendship were on full display at Dowling Catholic High School Tuesday night as one of their own families fights the repercussions of childhood cancer. Ava Foth, a sophomore at the school, underwent a bone marrow transplant on Tuesday. Ava was diagnosed with bone cancer in 2022. The treatment was successful, but Ava developed Myelodysplastic Syndrome, a rare form of cancer that comes from cancer treatment and impacts the bone marrow. John and Ava Foth were both recovering in the children's hospital on Tuesday. Her brother, John, a senior at the school and captain of the varsity soccer team, found out he was a bone marrow donor match for Ava, and did not hesitate to volunteer. His bone marrow was harvested in a procedure on Monday, roughly 24 hours before it was transplanted into Ava. That has caused him to miss out on leading his team for several games. Despite the family being at the University of Iowa Stead Family Children's Hospital in Iowa City on Tuesday night, the school honored them during the 7:30 p.m. varsity soccer home game. Dozens of rescued bats released back into the wild in Des Moines 'It's feels good to know that people are checking in, and they care about us and they are praying for us,' said Michelle Foth, as she held back tears. 'It's kind of hard to put into words everything they're doing to surround our family with love and support.' Michelle spoke to WHO 13's Katie Kaplan via FaceTime from John's hospital room. The mother and son had been able to see how their school community was honoring them through the lens of a friend's cell phone. 'In this family, no one fights alone,' said one sign that greeted people as they entered the stadium. The evening included free yellow ribbons for spectators (a symbol of bone cancer), signs of encouragement for Ava and John, the entire team warming up in specialty shirts bearing John's team number, and lots of prayers. 'The support is great, but it's Ava, who's going through this,' said John, who was sore but in good spirits during his recovery. The crowd also participated in a symbolic wave, which mirrored a Hawkeye football tradition where fans in the University of Iowa's Kinnick Stadium wave to patients and families at the children's hospital just across the street. 'It's been really hard to watch them struggle through this,' said Blythe Stanfel, a close friend of Michelle's. 'But we know that they have faith and (sic) that God has a plan, and they're they're trusting and they're hoping and just relying on the Lord.' 'The whole family, they are so nice,' said John's former co-captain Henry Abaraca. 'Some of the nicest people I've ever met.' Abaraca graduated last year, but has remained close with John. He said he would often play video games with Ava during her first cancer treatment to help pass the time in the hospital, and said he was happy to support the family in any way he could. 'I'm glad that I can help her just kind of, you know, feel free and not have to worry about all the stuff that's going on, he said. Michelle said Ava's transplant, which had taken place only a few hours prior, had gone well and that the next few weeks ahead would be focused on recovery for both children. 'We'll be here in the hospital for quite some time,' said Michelle. 'We'll just do everything we can to keep her healthy and safe.' The Foth family encourages people to look into the donor registry. All it takes is one swab to see if you are a match to save a life. To sign up to be a bone marrow donor, visit the National Marrow Donor Program Website. Metro News: Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. For the latest news, weather, sports, and streaming video, head to
Yahoo
16-04-2025
- Health
- Yahoo
NC House Republican could return to Raleigh soon after sharing cancer diagnosis
Good morning and welcome to Under the Dome. I'm Caitlyn Yaede. First, an update from Avi Bajpai about a House member's cancer diagnosis and when he could return to the legislature. Rep. Mike Clampitt, a Republican from Western North Carolina serving his fourth term in the House, announced last week that he has been diagnosed with a rare form of blood and bone marrow cancer. Clampitt shared the news with constituents on Friday, writing in his weekly newsletter that he had been diagnosed with Myelodysplastic Syndrome and had decided to avoid public gatherings for the time being to protect his health, according to Blue Ridge Public Radio. 'This is undoubtedly one of the most difficult periods of my life, but I remain hopeful and grounded by the unwavering support of my family, friends and this incredible community,' Clampitt said. The treatment was expected to keep Clampitt away from the General Assembly for a while, but House Majority Leader Brenden Jones said on Tuesday that he's been in close contact with Clampitt. He believes he's been responding 'very well' and may be able to return to Raleigh as early as today. 'We've been rallying around him to make sure he had all the support he needs,' Jones said. 'My understanding is he did a few days in the hospital, is doing a lot better, and I think he may even be joining us tomorrow.' The House is moving several bills through committees this week and taking them up on the floor as the Senate advances its budget proposal. Both chambers will be out next week. Sen. Kevin Corbin, a Republican whose district includes the same counties as Clampitt's district, told The N&O he and a few other House members found out about Clampitt's diagnosis from him about a month ago. Corbin said Clampitt 'has got a heart of gold' and loves representing Jackson, Swain and Transylvania counties in Raleigh. He said the legislature 'is a big part of what he considers his family.' 'We're very, very sorry he's having to go through this illness, and we're praying for him and offering any kind of help we can while he goes through this difficult time,' Corbin said. A majority of North Carolinians do not like the direction the country is headed in under President Donald Trump, according to a new poll this week from Meredith University. The poll, conducted earlier this month, asked residents their opinions on the country's direction as well as the economy and found that 60% of respondents were 'dissatisfied' with the current direction of the country. Similarly, only one in four respondents reported their finances were in 'good' or 'excellent' shape. Less than one-third — 31% — said the economy was strong, and 53% were concerned about the impacts of Trump's tariffs on the economy. His approval rating is an average of 4% lower among North Carolinians than in his first term. The Senate unveiled its budget plan on Monday evening, making it the first chamber to do so this year. It included raises for educators and state employees, as well as plans to slash vacant roles and some offices. The proposed budget outlines $32.6 billion in spending in the first fiscal year, and $33.3 billion in the second. The Senate hopes to restore the state's rainy day fund to its pre-Helene total of $4.75 billion, as well as send an additional $700 million to a Helene reserve fund. Under the Senate's proposal, teachers would see a 2.3% raise in the first year, and a 3.3% raise on average over two years, as well as a $3,000 bonus. Most state employees would see raises of 1.25%, with law enforcement and corrections officers seeing much higher increases. Find out more on raises in this story from Dawn Vaughan. The Senate opened the door to eliminating some of the state's vacant roles. The vacancy rate for state jobs is at 20%. The budget affirms the creation of a new agency inside the state auditor's office, called the Division of Accountability, Value and Efficiency. Echoing the Trump-created Department of Government Efficiency, DAVE would investigate potential waste in the state bureaucracy and deliver recommendations to the legislature. Read what's in the Senate's full fiscal plan, how it stacks up to Gov. Josh Stein's proposed budget, and when we can expect a version from the House. While the Senate's version of the budget supports the creation of a DOGE-like office in North Carolina, it also calls for cuts to two programs that some say are vital. The first of these 'targeted reductions' is to the Office of Historically Underutilized Businesses. Part of the Department of Administration, the office helps minority-owned businesses compete for government contracts, Avi Bajpai reports. While eliminating the office would save the state $1.7 million over the next two years, Sen. Gladys Robinson, a Greensboro Democrat, raised concerns over cutting the program. She says it has been effective at creating access for minority business owners. The Senate also proposed getting rid of the Innocence Inquiry Commission — established in 2006 to investigate wrongful convictions, Luciana Perez Uribe Guinassi reports. Since its creation, the commission says its work has led to 15 exonerations. House Speaker Destin Hall and his wife, Madison Skeens Hall, welcomed their first child on Tuesday. Hall is a Republican from Caldwell County and lives in Granite Falls. They are both lawyers. The Halls' son is named Henry Reece Hall. The news was announced during the afternoon House session by House Majority Leader Brenden Jones, who said Henry 'made his appearance at 2:06 p.m. today, weighing 7 pounds, 6 ounces, 20 inches long. Mom and baby are doing great.' Speaker Hall had previously told reporters their baby was due in early May. House Speaker Pro Tempore Mitchell Setzer presided Tuesday in Hall's absence. Jones posted a video of the House floor announcement on social media, which Hall shared with the words, 'Some personal news' followed by a baby emoji. Congratulations soon poured in, including from former N.C. House Speaker and current U.S. Rep. Tim Moore. After the Senate session, and while the House was still in session, Senate leader Phil Berger was asked if he had any advice for Hall. 'Just realize that the time goes by fast, and that child will be going off to college sooner than he thinks,' Berger said. — Dawn Baumgartner Vaughan and Avi Bajpai North Carolina Supreme Court Justice Allison Riggs is asking a federal appeals court to block a controversial ballot cure period from taking effect that could result in her 2024 victory being overturned. Riggs, a Democrat, narrowly defeated Republican Court of Appeals Judge Jefferson Griffin by 734 votes in November's Supreme Court election. But Griffin, alongside the NC GOP, has sought to throw out over 65,000 votes in the race using untested legal methods. Last week, the state Supreme Court ruled that the vast majority of the challenged voters — over 60,000 — would not have their votes thrown out. But a smaller number of military and overseas voters who Griffin challenged for not providing photo ID — still enough to flip the results — would be given 30 days to prove their eligibility to election officials or have their votes discarded. An even smaller number of voters, about 250, would have their votes cancelled without any opportunity to correct them. On Monday, Riggs filed a notice of appeal, saying that she will ask the 4th Circuit U.S. Court of Appeals to temporarily block this ruling from taking effect. The State Board of Elections is expected to provide details soon on exactly how many voters would be required to cure their ballots under the court's remedy. — Kyle Ingram Judges in Wake County Superior Court heard arguments over control of the State Board of Elections on Monday, Kyle Ingram reports. Gov. Josh Stein is challenging a Republican measure that would shift control of the board, and its 100 constituent county boards, to the state auditor. An attorney representing Republicans in the legislature said it is up to the General Assembly to delegate these powers, arguing they should be handed over to Dave Boliek. Unless a court intervenes, Boliek is slated to assume control over the election boards on May 1. Boliek joined the lawsuit, saying his position is less political and better suited for the job. The judges did not issue a ruling yet, although control of the election boards could have major impacts on the ongoing battle for Justice Allison Riggs' seat on the state Supreme Court. Durham County Sheriff Clarence Birkhead penned a three-page letter to county leaders, claiming his department was critically underfunded, citing operational and maintenance issues in county jails and courthouses. But county commissioners say they've addressed Birkhead's concerns, and that the department is operating with a surplus. The department underspent by $1.84 million last fiscal year, and $1.96 million the year before that. Lexi Solomon has the full story. A watchdog legal group accused Cabarrus County commissioners of appointing a new board member illegally, The Charlotte Observer's Joe Marusak reports. The group filed a lawsuit, claiming the vote for a new member was held with only three of the five commissioners present — and that it was intentionally held at a time when one commissioner was undergoing dialysis. Commissioners were replacing Chairman Christopher Measmer, who was sworn in Tuesday to a state Senate seat, replacing Paul Newton. Today's newsletter was by Caitlyn Yaede, Avi Bajpai, Dawn Vaughan and Kyle Ingram. Check your inbox tomorrow for more #ncpol. Not a subscriber? Sign up on our website to receive Under the Dome in your inbox daily.
Yahoo
24-03-2025
- Politics
- Yahoo
Eldon Strong, 1953-2025: Former Crown Point deputy chief, Lake County Councilman dies
Former Crown Point Police deputy chief and Lake County Councilman Eldon Strong died Saturday after a year-long battle with a rare blood cancer, according to his family. He was 72 years old. A year ago, Eldon Strong was diagnosed with Myelodysplastic Syndrome, which is a rare blood cancer where a person doesn't have enough healthy blood cells, said his wife Pauline Strong. He was taking medications, she said, but about two weeks ago the medication stopped working, she said. Eldon Strong served in the U.S. Marines Corps after graduating from Crown Point High School. After an honorable discharge, he joined the Crown Point Police Department, where he served for 35 years, rising through the ranks to become deputy chief and detective commander, according to his obituary. Crown Point Mayor Pete Land said in a statement that he was hired as a police officer when Eldon Strong was the deputy chief of police, 'so his leadership had a tremendous impact on my early career as a young officer.' 'Throughout his long law enforcement career, he was a dedicated officer for our community and helped build our police department into what it is today,' Land said. 'He challenged all of us to put the community first and serve our city in a professional matter, that we represent not only ourselves but our department.' Bill Babjak, a former Crown Point police officer, said Eldon Strong joined the department three years after he did, and they served together and became friends whose friends grew up together. 'We always knew we had each other's back,' Babjak said. Additionally, Eldon Strong served a four-year term on the Center Township Board, 10 years as Center Township Trustee and six years on the Lake County Council, according to his obituary. Sen. Rick Niemeyer, R-Lowell, said when he won his race to become state representative, he had two years left as a councilman. So Niemeyer asked Eldon Strong to run in the caucus for the vacant seat, and he won. Then, Eldon Strong ran and served a full four-year term, Niemeyer said. 'He did everything he needed to do for his district,' Niemeyer said. 'Whatever Eldon Strong told you, you could trust 100%. He was a man of his word.' Cedar Creek Township Trustee Alice Dahl said as a councilman, Eldon Strong helped all the trustees in Lake County receive funding through local income tax to go toward public safety, which was a tremendous benefit to the county. 'Eldon was just the best guy,' Dahl said. 'He would listen to you, and then run with the ball.' Council President Christine Cid, D-East Chicago, said she 'had the honor' of serving on the council along with Eldon Strong. 'His priority was serving his constituents,' Cid said. 'My condolences to his family and all who had the pleasure of his company.' Lake County Council attorney Ray Szarmach said Eldon Strong continued to support law enforcement during his time as a councilman as he served as chairman of the negotiating committee with the Lake County Sheriff's Department. Eldon Strong would not back down on issues important to him and his constituents, Szarmach said, and he stood by his convictions. 'He always acted in a manner he thought best for the taxpayers and citizens of Lake County,' Szarmach said. 'He was a man of integrity.' Pauline Strong said she went to high school with Eldon Strong, but after graduation, they lost touch. Years later, they reconnected and became friends again, she said. Ultimately, Pauline Strong said they were both on and matched together. After a few emails, they realized they knew each other and started dating, she said. 'We got together, and we've been together ever since,' Pauline Strong said. They had been together about 20 years, she said. Eldon Strong is survived by two daughters, a stepson, three granddaughters, a grandson, a sister and a brother, according to his obituary. Her husband was a happy, joyful man who had many friends, Pauline Strong said. The couple lived on Main Street in Crown Point, so the Fourth of July parade always meant a large party was held at their house, she said. 'If you became a friend of Eldon's, you basically became a friend for life,' Pauline Strong said. 'He was the best friend anyone could have.' The couple enjoyed fishing together and with friends, she said. 'He was the organizer in our group. He organized everything, down to his funeral,' she said. A wake will be held from 12 p.m. to 6 p.m. Sunday, March 30, at Burns Funeral Home and Crematory, 10101 Broadway in Crown Point. A funeral service will be held at 11 a.m. Monday, March 31, at Burns Funeral Home and inurnment at Historic Maplewood Cemetery in Crown Point. akukulka@
